BioMarin enters exclusive worldwide license for investigational Fabry therapy
BioMarin will make an upfront payment of $70 million for HM15421/GC1134A and may receive up to $405 million in milestone payments. The company will assume sole responsibility for all subsequent clinical development, manufacturing and commercialization outside of Korea.
Primary source
Company press release (PR Newswire), October 29, 2026
BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease
Machine-summarized from the source above; not independently reported. How we use automation